Buti M, Brosa M, Casado MA, Rueda M, Esteban R
Modeling the long-term cost-effectiveness of chronic hepatitis B therapies in Spain
11th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Athens, Greece. 8-11 nov 2008
Deniz B, Buti M, Brosa M, Casado MA, Rueda M, Everhard F, Esteban R
Cost-effectiveness simulation analysis of tenofovir disoproxil fumarate, lamivudine, adefovir dipivoxil and entecavir of HBeaAg negative patients with chronic hepatitis-B in Spain
43rd Annual Meeting of the European Association for the Study of the Liver (EASL). Milan, Italy. 23-27 apr 2008
Grau S, de la Cámara R, Carreras E, Sanz M, Jarque I, Casado MA, Sabater FJ, Papadopoulos G
Cost-effectiveness of posaconazole vs. fluconazole in the prevention of invasive fungal infections among patients with graft-versus-host disease in Spain
18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Barcelona, Spain. 19-22 apr 2008
Grau S, de la Cámara R, Sanz M, Carreras E, Jarque I, Casado MA, Sabater FJ, Papadopoulos G
Cost-effectiveness of posaconazole versus standard azole treatment (fluconazole or itraconazole) in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain
18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Barcelona, Spain. 19-22 apr 2008
Buti M, Brosa M, Casado MA, Rueda M, Esteban R
Estimación de la morbilidad, mortalidad y costes asociados a la evolución de la hepatitis crónica B en España
XXXIII Congreso Nacional de la Asociación Española para el Estudio del Hígado (AEEH). Madrid, España. 20-22 feb 2008
Buti M, Brosa M, Casado MA, Rueda M, Esteban R
Estimating the impact of chronic hepatitis B on future liver-related morbility, mortality and cost in Spain
58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, Massachusetts, EEUU. 2-6 nov 2007
Buti M, Casado MA, Esteban R
Evaluating the cost of sustained virologic response in naïve chronic hepatitis C patients treated a la carte
Aliment Pharmacol Ther. 2007;26:705-16
Casado MA, Benavides M, Cajaraville G, Carreras MJ, Tabernero JM
Análisis coste-eficacia y de impacto presupuestario del tratamiento en primera línea del cáncer colorrectal metastásico en España
Rev Esp Econ Salud. 2007;6:106-18
Buti M, Casado MA, Esteban R